Off-Label Trades (@OffLabelTrades) header
Off-Label Trades (@OffLabelTrades) profile picture

Highlighting interesting and unusual options trades in biotech and pharma. Not financial advice, DYOR.

Joined July 2025
Photo by Off-Label Trades (@OffLabelTrades)Photo by Off-Label Trades (@OffLabelTrades)Photo by Off-Label Trades (@OffLabelTrades)Photo by Off-Label Trades (@OffLabelTrades)Photo by Off-Label Trades (@OffLabelTrades)Photo by Off-Label Trades (@OffLabelTrades)Photo by Off-Label Trades (@OffLabelTrades)Photo by Off-Label Trades (@OffLabelTrades)Photo by Off-Label Trades (@OffLabelTrades)Photo by Off-Label Trades (@OffLabelTrades)
Off-Label Trades retweeted
Replying to @ScorpionFund
At least your $SLNO report was based on actual in-human data. What you're saying about $ABVX is late to the story wet lab speculation that has already debunked by the existing in human data which very clearly show malignancy rates within or below the expected background rates...Which even your own tables show! BTW, you seem not to know this, but institutional investors ran these lab studies that you just did years ago already, and those same people ended up becoming some of the company's biggest bulls and current investors. I know you think you published something new here - you didn't. The AhR stuff is old old news. Years late to the story, and the in human data have already played out to $ABVX's favor. I could go on and on listing the absurdities in this document...discussing monkey tox concerns at 500mg/kg/day (~1000x the human dose!!!), concerns over "Chinese data" when ABTECT-2 had literally ZERO Chinese trial sites. You point out preclinical phototoxicity signals and speculate that the company didn't know or didn't do anything about it...yet enhanced skin surveillance was BUILT INTO THE STUDIES PROSPECTIVELY by the company! The company itself not only knew about this, but literally specifically designed the studies to test phototox concerns and either confirm it or rule it out....WHICH IT ULTIMATELY DID rule out. Pointing out that the parent molecule is lipophilic and using that to call it an "agrochemical"... Just laughable sensationalism. We have known the structure of this molecule for over a decade. And BTW, plenty of drugs have lipophilic properties. This is a bizarre and irresponsibly over-sensationalized bit...calling it an "agrochemical"... BTW, your own malignancy event table shows a malignancy rate BELOW background rates....??? You point out that there were zero remissions the placebo arm in one of the trials in the US and call that an outlier that will concern regulators....the expected number of patients to respond in that arm per the results of the rest of the study would have been 1.6 responders on the placebo arm! 0 instead of 1...that's an anomolous signal to you? So ultimately your bear argument is this: "This drug has NOT shown increases in cancer in patients. In fact, it has shown rates at or even BELOW the rates of other drugs approved for this disease that have no black box warning for cancer. But hey, who knows, maybe that will change someday down the road!" BTW, you're aware there's an FDA approved AhR drug on the market already right? One with no cancer risk... You're claiming that AhR agonism is the top secret *true* mechanism of $ABVX's obefazimod and that this is bad because you claim AhR agonism is going to cause cancer... Again, not only is the AhR agonism theory that you're treating as a revelation actually a point that $ABVX *bulls* have believed for literally years already (i.e. not news from you), but there is actually a drug ON THE MARKET today that literally has that as its exact mechanism of action...and it has no labeled risk of carcinogenicity and no studies in humans or animals supporting carcinogenic risk....So you go through all this bluster about AhR pretending it is news (it isn't) and then claiming it is going to cause cancer (even though the data we have very clearly show that it HASN'T), meanwhile, there's already been an AhR drug on the market for years that has never shown a single piece of evidence for carcinogenicity... Like I have said in the past - I had previously agreed with some of your work. This piece is irresponsibly poorly done and the use of the word "fraud" is absolutely egregious and slanderous when your thesis ultimately boils down to..."well, they haven't shown cancer signals yet, but maybe they will someday!" Calling this fraud with the evidence you provide sincerely rises to the level of libel, in my opinion.
9
18
2
203
10,160
Off-Label Trades retweeted
$ABVX Scorpion report is just silly. The entire argument is based on preclinical wet lab "research". The report makes all these outlandish claims about what the drug "might" do based on their lab work, then ignores that all of those potential "problems" have been completely debunked by ACTUAL REAL WORLD DATA. The drug is post phase 3 already people. We already know the safety profile. The theories they published in this "short report" are *literally* the exact bear theses people were talking about 6 years ago for $ABVX. Wet lab based *theories* about the molecule itself. The difference today is that.....we literally have all the real world in human data now, AND NONE OF THOSE SCARY THEORIES TURNED OUT TO BE TRUE. I'm with @Biohazard3737 - I increased by exposure to $ABVX this morning. I suspect that this report coming out also explains the recent weakness in the stock. Scorpion has supposedly been working on this for 11 months. Word going around about this report is probably what caused that short report rumor and flash crash back in June too. And since then, we got EVEN MORE data proving the safety concerns are debunked. I have been baffled by even seeing the stock languishing in the $80s recently. Now I understand why that's been the case. I've already talked to a lot of smart people on this. The near universal response is laughter/mockery. This is simply not serious work. Congrats to Scorpion though for finding a weak stock to attack and then cover your short on a Friday Opex. $ABVX will be fine.
38
26
7
347
28,059
Off-Label Trades retweeted
$ABVX All I have to say is that if any of these was true FDA, EMA and worldwide health agencies would have placed clinical hold by now and not let trials run for 10+ years. Good luck.
NEW: We are short $ABVX Abivax SA - a biotech fraud for the ages. Report now live on our site, along with four scientific abstracts based upon our laboratory experiments. An 11-month investigation, our most intensive research to date.
1
3
1
119
4,749
Off-Label Trades retweeted
As a chemist who has worked on anthelmintics, this report is one of the most vulgar displays of overinterpreting LogP I think the human mind is capable of. My guess this started w/ "Claude, is there anything weird about this molecule?"
2
18
1
120
6,631
Off-Label Trades retweeted
Below is the story of the first patient treated with a prime-edited therapeutic, developed by @PrimeMedicine in a trial led by Dr. Élie Haddad and his team at CHU Sainte-Justine. This teenager suffered from chronic granulomatous disease (CGD), an immunodeficiency, and now—10 months after treatment—the patient is healthy, stable, and living with a functioning immune system. Tracy Attebury, whose story was previously told by @ginakolata @nytimes, was the second patient treated with a prime-edited therapeutic. cihr-irsc.gc.ca/e/54638.html
29
163
34
879
175,255